Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) COO Steve Miller Sells 80,000 Shares

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRXGet Rating) COO Steve Miller sold 80,000 shares of the stock in a transaction that occurred on Monday, November 21st. The shares were sold at an average price of $15.28, for a total value of $1,222,400.00. Following the completion of the sale, the chief operating officer now directly owns 573,791 shares of the company’s stock, valued at approximately $8,767,526.48. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Steve Miller also recently made the following trade(s):

  • On Wednesday, November 23rd, Steve Miller sold 20,000 shares of Catalyst Pharmaceuticals stock. The stock was sold at an average price of $17.34, for a total value of $346,800.00.
  • On Tuesday, September 13th, Steve Miller sold 107,933 shares of Catalyst Pharmaceuticals stock. The stock was sold at an average price of $16.90, for a total value of $1,824,067.70.

Catalyst Pharmaceuticals Trading Down 2.7 %

Shares of NASDAQ CPRX opened at $17.03 on Thursday. The stock has a market capitalization of $1.77 billion, a PE ratio of 27.92 and a beta of 1.27. The stock has a fifty day simple moving average of $13.72 and a 200-day simple moving average of $11.05. Catalyst Pharmaceuticals, Inc. has a twelve month low of $5.24 and a twelve month high of $17.76.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the company. Piper Sandler raised their target price on Catalyst Pharmaceuticals to $18.00 in a research note on Wednesday, November 16th. Roth Capital cut Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and raised their target price for the stock from $10.00 to $15.50 in a research note on Wednesday, August 24th. StockNews.com cut Catalyst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 9th. Truist Financial lifted their price objective on Catalyst Pharmaceuticals from $12.00 to $17.00 and gave the company a “buy” rating in a research note on Thursday, August 11th. Finally, HC Wainwright lifted their price objective on Catalyst Pharmaceuticals from $12.00 to $18.00 and gave the company a “buy” rating in a research note on Thursday, August 11th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $17.13.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Teachers Retirement System of The State of Kentucky purchased a new position in Catalyst Pharmaceuticals in the third quarter valued at $383,000. Advisory Research Inc. purchased a new position in Catalyst Pharmaceuticals in the third quarter valued at $623,000. Balyasny Asset Management LLC purchased a new position in Catalyst Pharmaceuticals in the third quarter valued at $443,000. BNP Paribas Arbitrage SNC boosted its holdings in Catalyst Pharmaceuticals by 814.9% in the third quarter. BNP Paribas Arbitrage SNC now owns 282,017 shares of the biopharmaceutical company’s stock valued at $3,618,000 after purchasing an additional 251,191 shares during the period. Finally, State Street Corp boosted its holdings in Catalyst Pharmaceuticals by 39.0% in the third quarter. State Street Corp now owns 7,555,423 shares of the biopharmaceutical company’s stock valued at $96,936,000 after purchasing an additional 2,117,944 shares during the period. 74.16% of the stock is currently owned by hedge funds and other institutional investors.

About Catalyst Pharmaceuticals

(Get Rating)

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.

See Also

Insider Buying and Selling by Quarter for Catalyst Pharmaceuticals (NASDAQ:CPRX)

Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.